UNSPSC 51102873: Sulfabenzamide/sulfacetamide/sulfathiazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.

UNSPSC 51102873 Sulfabenzamide/sulfacetamide/sulfathiazole is a Commodity code for pharmaceutical products, though the recent state and local opportunities posted under this code show minimal alignment with its nominal scope. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets, and Seminole County, Florida solicited Naloxone and drug deactivation systems. Neither opportunity directly matches the sulfabenzamide/sulfacetamide/sulfathiazole class name, suggesting the code may be misapplied in tagging or that state and local purchasing systems are using it as a catch-all for pharmaceutical procurement more broadly. The issuing bodies are state departments and counties; state health departments appear to be primary users of pharmaceutical piggyback contracts through established cooperative purchasing frameworks.

Recent activity spans Florida and Illinois. The Illinois Department of Public Health's Chartwell Rx LLC contract, awarded August 28, 2026, was structured as a piggyback to an existing MMCAP Infuse consortium agreement with an initial 12-month term and renewal options through year 3, totaling $2,999,999.11 over the full contract life. Seminole County's IFB for Naloxone and drug deactivation systems, posted June 30, 2026, required quarterly deliveries of 1,900 Naloxone units and 800 deactivation systems annually to the Seminole County Community Health Building in Sanford, with a two-year initial term and one-year renewal option. The code shows limited recent activity and a disconnect between its nominal scope and actual recent procurement, which may reflect data-quality issues rather than active market demand in this specific pharmaceutical category.